


Systematic Pubmed search about hypogammaglobulinemia as an outcome of Rituximab treatment in NMOSD patients.

Selection of the most sensitive and specific search query (with the most relevant items as a result).



Reference	Results	Context
Radaelli M, Moiola L, Sangalli F, et al. Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. <i>Mult Scler J.</i> 2015;1-9.	Persistent IgG deficit after the first RTX course was detected in 11 patients (52%), associated with IgM deficit in 5/11 patients. Serious infectious complications occurred in five patients.	21 patients involved. Mean follow-up: 48 months.
Kim S-H, Jeong IH, Hyun J-W, et al. Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab. <i>JAMA Neurol.</i> 2015;72(9):989-995.	Low IgM, IgG, and IgA levels occurred in 53%, 29%, and 10% of the treated patients respectively. The infection rates were not increased in patients with low IgG or IgM levels.	41 patients treated for more than 5 years.

<p>Graves J, Vinayagasundaram U, Mowry EM, et al. Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica. <i>Mult Scler Relat Disord.</i> 2014;3(2):244-252.</p>	<p>No significant change in IgM ($p=0.06$) or IgG ($p=0.45$) levels after RTX treatment.</p>	<p>16 NMOSD patients.</p>
<p>Pellkofer HL, Krumbholz M, Berthele A, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. <i>Neurology.</i> 2011;76(15):1310-1315.</p>	<p>Low Ig levels were detected in 2/10 patients, who experienced infectious adverse effects.</p>	<p>10 NMOSD patients Mean follow-up: 30 months.</p>
<p>Jacob A, Weinshenker BG, Violich I, et al. Treatment of Neuromyelitis Optica With Rituximab. <i>Arch Neurol.</i> 2008;65(11):1443-1448.</p>	<p>20% of patients developed infectious complications. One patient had fatal infectious adverse effect, during a hypogammaglobulinaemia period.</p>	<p>25 NMOSD patients Mean follow-up: 19 months.</p>